Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Akero Therapeutics, Inc. (AKRO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins",
"Slide presentation of Akero Therapeutics, Inc"
08/11/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update"
05/17/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and between the Company and Jefferies LLC, as representative of the several underwriters named therein",
"Opinion of Goodwin Procter LLP",
"Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock South San Francisco, CA - May 16, 2023 - Akero Therapeutics, Inc. , a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the pricing of an underwritten offering of 5,238,500 shares of its common stock at a price of $42.00 per share, before deducting underwriting discounts and commissions, for total gross proceeds of approximately $220.0 million. All of the shares to be sold in the offering are being sold by Akero Therapeutics. The financing was led by new investor General Atlantic and included existing investors Adage Capital Partners LP, Avidity Partners, Boxer Capital, Commodore Capital, Janu..."
05/15/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update"
03/29/2023 8-K Quarterly results
03/17/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "Open Market Sale AgreementSM, by and between Akero Therapeutics, Inc. and Jefferies LLC",
"Legal Opinion of Goodwin Procter LLP"
03/17/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results SOUTH SAN FRANCISCO, March 17, 2023 /GLOBE NEWSWIRE/ - Akero Therapeutics, Inc. , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2022. “The wins we celebrated in 2022 further solidify our confidence in efruxifermin as a potential best-in-class FGF21 analog addressing all core drivers of NASH disease progression,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “The statistically significant histology and secondary endpoint results from September's topline HARMONY trial readout followed by E..."
11/04/2022 8-K Quarterly results
09/16/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and between the Company, J.P. Morgan, Morgan Stanley and Jefferies, as representatives of the several underwriters named therein",
"Opinion of Goodwin Procter LLP"
09/13/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "In Akero Therapeutics' Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks",
"Slide presentation of Akero Therapeutics, Inc"
08/04/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
02/25/2022 8-K Quarterly results
12/10/2021 8-K Quarterly results
11/12/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
11/12/2021 8-K Quarterly results
Docs: "Investor Contact:"
09/09/2021 8-K Quarterly results
08/13/2021 8-K Quarterly results
07/14/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/25/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results
06/02/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
04/26/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/22/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/16/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Corporate slide presentation of Akero Therapeutics, Inc"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy